UEEC - United Health Products, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.9800
-0.0400 (-1.98%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.0200
Open2.0400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.8500 - 2.1900
52 Week Range0.3000 - 2.1900
Volume895,124
Avg. Volume156,586
Market Cap348.91M
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateJan 15, 2019 - Jan 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    United Health Products Announces Completion of Pathology and Study of Preclinical Bone Application of HemoStyp®

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had received the pathology results of a preclinical animal study to assess the effect of HemoStyp on the bone. This study and indication is independent of the current PMA application and will potentially allow UHP acess to a new and significant market opportunity. UHP believes that these preliminary results demonstrate the safe application of HemoStyp in orthopedic procedures.

  • GlobeNewswire

    United Health Products Files New Patent Application Method of Forming and Using a Hemostatic Hydrocolloid

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, today announced that it has filed a patent application covering methods of forming and using a hemostatic material, and more specifically, methods of forming and using a hemostatic hydrocolloid that is formed into a gel, foam or spray used to control bleeding and oozing from a variety of wounds. Upon approval of the new patent, this will allow for the HemoStyp hydrocolloid to act as a conduit to transfer other properties associated with the treatment of wounds within the hydrocolloid. “This enables HemoStyp to be bundled as a suite of multiple products for surgical and wound care applications,” said Louis Schiliro, COO, UHP.

  • GlobeNewswire

    United Health Products Announces the Completion of Human Trial Surgery Enrollment

    HENDERSON, Nev., Aug. 05, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Issues Shareholder Update

    It expects to complete enrollment and all surgical procedures for its human clinical trial on or around mid-July 2019. David W. Ramey DVM has prepared a presentation —How to Use a Hemostatic Gauze Product to Help Control Bleeding in Clinical Settings in the Horse— which will be published in the Journal of Veterinary Emergency and Critical Care.

  • GlobeNewswire

    United Health Products Announces Completion of IQVIA Independent Market Assessment for HemoStyp® in Support of Review of Strategic Alternatives

    HENDERSON, Nev., May 07, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the.

  • GlobeNewswire

    United Health Products Retains IQVIA to Conduct U.S. Market Commercialization Study of HemoStyp® in Support of Société Générale’s Strategic Review

    HENDERSON, Nev., April 24, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or “the company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Announces 2018 Results

    United Health Products, Inc. (UEEC) (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today filed its Form 10-K for the year ended December 31, 2018. Douglas K. Beplate, President and CEO said, “2018 was the most important year to date in our company’s development: we shifted our corporate focus to achieving FDA Class III approval for our products in human surgical applications.  We believe that gaining access to this $3.4 billion segment of the hemostatic gauze market is the best path to creating value for our shareholders and so we have devoted our resources fully to that objective. In February 2018, the Company completed and submitted to the U.S. Food and Drug Administration (“FDA”) all materials relevant for the pre-market approval (“PMA”) for HemoStyp under the FDA’s new and innovative CtQ Pilot-Program as a Class III application for internal surgical procedures.

  • GlobeNewswire

    United Health Products to Hold Conference Call on December 20, 2018 to Discuss Recent Corporate Developments and Provide Year End Update

    HENDERSON, Nev., Dec. 17, 2018 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), a manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Retains Legal Counsel Ruskin Moscou Faltischek P.C to Assist in Strategic Review

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had retained Ruskin Moscou Faltischek P.C. to assist it and Société Général in its previously announced Review of Strategic Alternatives. In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by a number of medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company’s board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan.